Welcome to our dedicated page for Ventas news (Ticker: VTR), a resource for investors and traders seeking the latest updates and insights on Ventas stock.
Ventas, Inc. is an S&P 500 real estate investment trust with a healthcare and senior housing property portfolio in North America and the United Kingdom. News about VTR commonly covers quarterly results, senior housing operating portfolio performance, occupancy and RevPOR trends, net operating income, healthcare real estate investments, dividends and tax treatment of distributions.
Company updates also address investor presentations, earnings calls, capital allocation and portfolio categories that include senior housing communities, outpatient medical buildings, research centers and healthcare facilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Land & Buildings Investment Management has voiced dissatisfaction with Ventas (NYSE: VTR), expressing concerns over its ongoing underperformance and undervaluation. In a letter to the Board, they announced intentions to vote against Lead Independent Director James Shelton and Chair Debra Cafaro at the upcoming Annual Meeting on May 16, 2023. Notably, Ventas has underperformed against peer Welltower (NYSE: WELL), with a 26% discount in cash flow multiple and a 130 basis points higher cap rate. Furthermore, Ventas is projecting a decline in Funds from Operations (FFO) in 2023 while Welltower anticipates growth. Land & Buildings emphasizes the need for significant changes in leadership and strategy to enhance shareholder value.
Integral Molecular, a key player in Philadelphia's biotech sector, has officially opened its new 32,000 square foot headquarters, which includes pandemic preparedness laboratories. This expansion at One uCity marks significant growth for the company, which will double its headquarter footprint and accommodate 200 employees, adding 100 new technology jobs. The facility will enhance Integral Molecular's capabilities in R&D and manufacturing, crucial for addressing future viral threats. The opening event featured local leaders, including Philadelphia Mayor Jim Kenney. The company has been instrumental in providing vital reagents during the COVID-19 pandemic and continues to contribute to advancing therapeutics against various viral diseases.